骨髓微环境在多发性骨髓瘤 CAR-T 治疗中的作用

INTRODUCTION: Multiple myeloma (MM) is a malignant tumor caused by abnormal proliferation of bone marrow (BM) plasma cells and is the second most common hematologic malignancy. A variety of CAR-T cells targeting multiple myeloma-specific markers have shown good efficacy in clinical trials.

However, CAR-T therapy still limits the insufficient duration of efficacy and recurrence of the disease. AREAS COVERED: This article reviews the cell populations in the bone marrow of MM, and discusses the potential way to improve the efficiency of CAR-T cells in the treatment of MM by targeting the bone marrow microenvironment. EXPERT OPINION: The limits of CAR-T therapy in MM may related to the impairment of T cell activity in the bone marrow microenvironment.

This article reviews the cell populations of the immune microenvironment and nonimmune microenvironment in the bone marrow of multiple myeloma, and discusses the potential way to improve the efficiency of CAR-T cells in the treatment of MM by targeting the bone marrow. This may provides a new idea for the CAR-T therapy of multiple myeloma.